ERBB2 and breast carcinoma: Moreover, the aptamer binding specificity was assessed for other two breast cancer cell lines, including MCF-7 (ER+, PR+, HER2-) and MDA-MB-453 (ER-, PR-, HER2+) by flow cytometry and microscopy (Fig. S2).